NCT02649972已完成2 期
Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 2
- 主要终点
- Best Overall Response
研究概览
简要总结
The purpose of this study is to find out what effects, good or bad, Cobimetinib has in patients with histiocytosis. Cobimetinib is an investigational oral medication that blocks MEK1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed histiocytic disorder or histologic findings compatible with a histiocytic disorder in the context of confirmatory radiologic findings confirmed by the enrolling institution.
- •One of the following:
- •Documentation of BRAF V600E mutation and inability to access of BRAF inhibitor or prior treatment with a BRAF inhibitor discontinued due intolerable side effects or toxicity prior to progression, -OR-
- •Documentation of wild-type BRAF V600 mutational status
- •Patients with BRAF-mutated ECD/LCH who have had disease progression on BRAF inhibitor therapy would be eligible but would require tissue biopsy (or available tissue) for genotyping before participating.
- •Measurable disease according to PET Response Criteria, confirmed by the MSK investigator radiologist, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria
- •Histiocytic disorder must be (a) multi-system disease or (b) disease that is recurrent or refractory to standard therapies, or (c) single-system disease with that is unlikely to benefit from conventional and less toxic therapies, based on the best available evidence (for example, CNS or cardiac infiltration, retroperitoneal fibrosis, prior chemotherapy, or other medical history or co-morbidities, etc)
- •Life expectancy > 12 weeks
- •Age ≥ 16 years
- •ECOG performance status ≤ 3 (May be converted from Karnofsky Performance Status)
- •Adequate bone marrow function as indicated by the following:
- •ANC > 1000/uL
- •Platelets ≥ 50,000/uL
- •Hemoglobin ≥ 8.5 g/dL.
- •Patients with cytopenias below these thresholds deemed to be the result of disease will be considered eligible.
- •Adequate renal function, as indicated by:
- •creatinine ≤ 1.5 the upper limit of normal (ULN) -OR-
- •Estimated creatinine clearance of > 50 ml/min
- •As for #7, patients with renal dysfunction deemed to be the result of disease will be considered eligible.
- •Adequate liver function, as defined by bilirubin ≤ 1.5 ULN
- •AND AST/ALT < 3 ULN
- •Ability to swallow pills
- •Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
- •Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. Effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- •Patients must be willing to consent for protocol #12-245 for IMPACT testing (for MSK patients ONLY).
排除标准
- •Prior treatment with a MEK inhibitor
- •Active infection requiring intravenous antibiotics
- •Pregnant, lactating or breast feeding women
- •Prior radiation therapy within the last 14 days
- •Unwillingness or inability to comply with study and follow-up procedures.
- •Any foods/supplements that are strong inhibitors or inducers of CYP3A are prohibited at least 7 days prior to initiation of and during study treatment
- •History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, RVO, or neovascular macular degeneration
- •The risk factors for RVO are listed below. Exclusion should be considered by clinical discretion if they have the following conditions:
- •Uncontrolled glaucoma with intra-ocular pressures > 21mmHg
- •Serum cholesterol ≥ Grade 2
- •Hypertriglyceridemia ≥ Grade 2
- •Hyperglycemia ≥ Grade 2
- •History of clinically significant cardiac dysfunction, unless deemed to be the direct result of disease, including the following:
- •Current unstable angina
- •Symptomatic congestive heart failure of NYHA class 2 or higher
- •Uncontrolled hypertension ≥ Grade 2 (patients with a history hypertension controlled with anti-hypertensives to ≤ Grade 2 are eligible).
- •Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or below 50%
- •Uncontrolled arrhythmias
- •Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack within the previous 6 months
研究组 & 干预措施
Cobimetinib
Experimental
This is an open-label, multicenter, phase II study exploring the efficacy and safety of single-agent Cobimetinib in patients with histiocytic disorders whose tumors are 1) BRAFV600 wildtype or 2) BRAFV600E mutant and are intolerant to, or unable to access, BRAF inhibitors. Visits during the treatment period are to be completed on Day 1, Day 15 (this visit can be by telephone), Day 29, and every 28 days thereafter. For patients treated on the study for six months, at the discretion of the Principal Investigator, visits can be spaced out to every 56 days (every 2 cycles instead of every cycle). After 24 cycles of treatment, if imaging demonstrates sustained stability in the opinion of the principal investigator, tumor assessments can be performed ever 1 year.
干预措施: Cobimetinib (Drug)
结局指标
主要结局
Best Overall Response
时间窗: 1 year
by PET Response Criterial (PRC), with a dichotomous BOR of CR or PR versus neither of those. Assuming we use this binary endpoint of response, defined as best overall response of CR or PR versus not using the PET Response Criteria (PRC), a sample size of 18 patients provides 90% power to test the hypothesis that the response rate is promising (defined as 35% or higher) against a non-promising rate of 10% or lower.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT03312530Hoffmann-La Roche49
已完成
2 期
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsSkin Squamous Cell CarcinomaAppendix AdenocarcinomaRare LesionLocally Advanced Malignant NeoplasmLocally Advanced Skin Squamous Cell CarcinomaMetastatic Malignant NeoplasmMetastatic Skin Squamous Cell CarcinomaMetastatic Small Intestinal AdenocarcinomaRare Neoplastic SyndromeRefractory Malignant NeoplasmStage IV Small Intestinal Adenocarcinoma AJCC v8Unresectable Malignant NeoplasmNCT03108131M.D. Anderson Cancer Center49
已完成
2 期
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal CancerColorectal CancerNon-Small Cell Lung CancerNCT01676714University of California, Davis10
已完成
1 期
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaMalignant MelanomaNCT03178851Hoffmann-La Roche155
终止
2 期
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibALK-positive Non-small Cell Lung CancerNCT04211922Suzhou Zelgen Biopharmaceuticals Co.,Ltd4